G1 Therapeutics, Inc.
Morphic forms of trilaciclib and methods of manufacture thereof
Last updated:
Abstract:
An advantageous isolated morphic form of trilaciclib which is 2'-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spir- o[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one, for example in the form of a di-hydrochloride salt or a dihydrochloride, dihydrate.
Status:
Grant
Type:
Utility
Filling date:
13 Nov 2020
Issue date:
27 Apr 2021